Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology

Galapagos to pay up to $27 million in upfront and preclinical milestone payments to BridGene

08-Jan-2024 - Galapagos NV announced that it has entered into a strategic collaboration and licensing agreement with BridGene Biosciences, Inc. (“Bridgene”), a biotechnology company that uses proprietary chemoproteomics technology to discover novel small molecule drug candidates. Through this collaboration, ...

Galapagos appoints Paul Stoffels as Chief Executive Officer

Succeeds current Chief Executive Officer and co-founder Onno van de Stolpe, following planned retirement

27-Jan-2022 - Galapagos NV announced the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles ...

Galapagos announces planned retirement of CEO

The Supervisory Board has initiated an external search for replacement

31-Aug-2021 - Galapagos NV announces the planned retirement of CEO Onno van de Stolpe. Onno van de Stolpe co-founded Galapagos in 1999 and built and led the company as CEO from its early R&D days through to the commercial launch of Jyseleca® (filgotinib) in Europe. Onno will retire and make way for a new CEO ...

Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration

26-Aug-2019 - Gilead Sciences, Inc. and Galapagos NV announced the closing of the global research and development collaboration agreement signed on 14 July 2019. This agreement has received clearance from the U.S. Federal Trade Commission under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and ...

Gilead and Galapagos Enter Into Transformative Research and Development Collaboration

15-Jul-2019 - Gilead Sciences, Inc. and Galapagos NV announced that they have entered into a 10-year global research and development collaboration. Through this agreement, Gilead will gain access to an innovative portfolio of compounds, including six molecules currently in clinical trials, more than 20 ...

Evotec and Galapagos enter into collaboration in the field of fibrosis

07-Feb-2019 - Evotec AG and Galapagos NV announced a global collaboration focused on a novel target for fibrosis and other indications. The collaboration concerns a small-molecule program, currently in pre-clinical drug development for the treatment of fibrotic diseases of the liver and other organs. The ...

Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106

17-Sep-2018 - Galapagos NV and MorphoSys AG announced the initiation of a Phase 1 bridging study testing a subcutaneous formulation of MOR106, an investigational antibody directed against IL-17C. This bridging study is a parallel-design Phase 1 clinical trial conducted in two parts. Part 1 is a single center, ...

MorphoSys and Galapagos Advance Joint Antibody Program in Inflammatory Diseases into Preclinical Development

25-Jul-2014 - MorphoSys AG and Galapagos NV announced that the first program from their strategic alliance has advanced into preclinical development. MOR106 was realized based on a novel Galapagos target and MorphoSys' next-generation antibody library Ylanthia and will now be jointly developed in inflammatory ...

BioFocus has signed an integrated drug discovery collaboration with Boehringer Ingelheim

21-Nov-2013 - Galapagos announced that its BioFocus subsidiary signed a new collaboration agreement with Boehringer Ingelheim. Under the terms of the agreement, BioFocus will apply its extensive drug discovery services to an undisclosed target within Boehringer Ingelheim’s drug discovery portfolio. David ...

Galapagos acquires Cangenix, a structure-based drug discovery company

18-Jan-2013 - Galapagos NV (GLPG) and Cangenix Ltd announced that Galapagos has acquired Cangenix to add structure-based drug discovery to the Argenta service offering. Under the terms of the acquisition agreement, Galapagos will pay a total cash consideration of £1 million, with a further £440,000 potential ...